Editorial: The coming revolution in the treatment of prostate cancer patients

Seminars in Urologic Oncology

Volumn 20, Issue 3 SUPPL. 1, 2002, Pages 1-3

  Petrylak, Daniel P ^a   De Wit, Ronald ^a  

^a Columbia Presbyterian Medical Center ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIETHYLSTILBESTROL; DOCETAXEL; ESTRAMUSTINE; FOLLITROPIN; GONADORELIN; GONADORELIN ANTAGONIST; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2;

BONE PAIN; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; EDITORIAL; HUMAN; METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; THROMBOEMBOLISM;

EID: 0036670484     PISSN: 10810943     EISSN: None     Source Type: Journal    
DOI: 10.1053/suro.2002.35050     Document Type: Editorial

References (23)

1. Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: Results from European Organization for Research on Treatment of Cancer trials 30761 and 30762
2. Is disease flare a problem?
3. Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate
4. Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide)
5. Maximum androgen blockade in advanced prostate cancer: An overview of the randomised trials
6. Development of GnRH antagonists for prostate cancer: New approaches to treatment
7. The gonadotropinreleasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: Initial results of endocrinological and biochemical efficacies in patients with prostate cancer
8. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer
9. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the Cancer and Leukemia Group B 9182 study
10. Taxol in advanced hormone-refractory prostate carcinoma: A phase II trial of the Eastern Cooperative Oncology Group
11. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer: Preliminary results
12. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer
13. Response and preliminary survival results of a phase II study of docetaxel (D) + estramustine (E) in patients (pts) with androgen-independent prostate cancer
14. A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: Preliminary results of Cancer and Leukemia Group B Trial 9780
15. Bcl-2 is the guardian of microtubule integrity
16. Unanswered questions in screening for prostate cancer
17. Prediction of locoregional extension and metastatic disease in prostate cancer: A review
18. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer
19. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma
20. The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results
21. Neoadjuvant hormone therapy before radical prostatectomy: Update on the Memorial Sloan-Kettenng Cancer Center trials
22. Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure
23. Neoadjuvant hormone therapy: The Canadian trials